Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Reuters

2025/10/13

Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575844383"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575844383\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575844383?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575844383","market":"nz","top_or_hot":-1,"title":"Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-13 06:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251012:nNDL1yqC1m:1","article_id":"2575844383","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575844383","pubTimestamp":1760306724,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology  Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","BK4588":"碎股","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念"},"translate_title":"Incyte在ESMO 2025上宣布KRAS G12D抑制剂和TGF β R2xPD1双特异性抗体的积极1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    \n\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}